|
|
||||||||||
|
J Am Coll Cardiol, 2007; 50:1442-1449, doi:10.1016/j.jacc.2007.06.039
(Published online 21 September 2007). © 2007 by the American College of Cardiology Foundation |
,*


* Division of Cardiovascular Medicine, Brigham and Womens Hospital, Boston, Massachusetts
Harvard Clinical Research Institute, Boston, Massachusetts
Lehigh Valley Hospital, Allentown, Pennsylvania
St. Vincents Hopsital, Indianapolis, Indiana
|| Velocimed/St. Jude Medical, Maple Grove, Minnesota.
Manuscript received May 8, 2007; revised manuscript received June 15, 2007, accepted June 25, 2007.
* Reprint requests and correspondence: Dr. Laura Mauri, Brigham and Womens Hospital, 75 Francis Street, Boston, Massachusetts 02115. (Email: lmauri1{at}partners.org).
Objectives: To determine if outcomes could be further improved, we investigated an embolic protection device placed proximal to the target lesion that could provide protection before lesion instrumentation, allow the use of conventional guidewires, and permit embolic protection in anatomy unfavorable for distal devices.
Background: Embolic complications during stenting of degenerated saphenous vein coronary bypass grafts are reduced, but not eliminated, by distal protection.
Methods: A total of 594 patients undergoing stenting of 639 saphenous vein grafts were prospectively randomized, using a noninferiority design, to compare 2 treatment strategies: control (distal protection whenever possible) or test (proximal protection when possible, distal when not).
Results: The primary composite end point of death, myocardial infarction, or target vessel revascularization at 30 days by intention to treat analysis occurred in 10.0% of control and 9.2% of test patients; difference = –0.8% (95% confidence interval [CI] –5.5% to 4.0%); p for noninferiority = 0.0061. In device specific analysis, this composite end point occurred in 11.7% of distal protection patients and 7.1% of proximal protection patients (difference = –4.6% [95% CI –9.6% to 0.3%]; p for superiority = 0.10, p for noninferiority = 0.001). Finally, in the subset of patients with lesions amenable to treatment with either proximal or distal protection devices (n = 410), the primary composite end point occurred in 12.2% of distal protection patients and 7.4% of proximal protection patients; difference = –4.7% (95% CI –10.4% to 1.0%), p for superiority = 0.14, p for noninferiority = 0.001.
Conclusions: Using proximal embolic protection whenever possible during treatment of diseased saphenous vein grafts produced outcomes similar to those with distal embolic protection.
| ||||||
This article has been cited by other articles:
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF] |
||||
![]() |
E. R. Bates Aspirating and Filtering Atherothrombotic Debris During Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 265 - 267. [Full Text] [PDF] |
||||
![]() |
A. Coolong, D. S. Baim, R. E. Kuntz, A. J. O'Malley, S. Marulkar, D. E. Cutlip, J. J. Popma, and L. Mauri Saphenous Vein Graft Stenting and Major Adverse Cardiac Events: A Predictive Model Derived From a Pooled Analysis of 3958 Patients Circulation, February 12, 2008; 117(6): 790 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al. Highlights of the year in JACC 2007. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512. [Full Text] [PDF] |
||||
![]() |
Proximal Protection for Saphenous Vein Graft Percutaneous Coronary Intervention Journal Watch Cardiology, December 12, 2007; 2007(1212): 7 - 7. [Full Text] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |